Clinical trials: Rejection Acute Renal
Humoral Rejection in Kidney Transplantation
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"
- Trial name
- RITUX-ERAH (NCT01350882)
- Testing
- MabThera, Physiological serum : sodium chloride, sodium citrate
- Where
- 30 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Tours
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Advances in renal transplantation have increased life-expectancy in patients with end-stage kidney disease. Conventional immunosuppressive drugs prevent efficiently early allograft losses due to T-cell mediated rejection.
- Trial name
- TAMARCIN (NCT02113891)
- Testing
- Eculizumab
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplantation
Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation
The purpose of this study is to determine whether bortezomib is effective in the treatment of acute cellular rejection after kidney transplantation.
- Trial name
- NCT02351427
- Testing
- Bortezomib, Steroid
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Kidney Transplantation, Graft Rejection
A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies
Patients who had received kidney transplantation may suffer from rejection. Recently, positive staining for C4d in kidney biopsies of malfunctioning transplant kidney is increasingly recognized as an important prognostic…
- Trial name
- NCT00498095
- Testing
- Renal biopsy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Hospital Authority, Hong Kong
HIV-1 Infection, Chronic Renal Insufficiency
Renal Transplantation and Raltegravir in HIV-Infected Patients
The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.
- Trial name
- ANRS153TREVE (NCT01453192)
- Testing
- Raltegravir
- Where
- 14 sites in France
- Volunteers
- 27 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Heart Transplantation
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function.
- Trial name
- NCT02554955
- Testing
- Daclizumab, Mycophenolate mofetil, Silrolimus
- Where
- 14 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00263328
- Testing
- Tacrolimus, CP-690,550
- Where
- 27 sites in United States
- Volunteers
- 46 people
- Sponsor
- Pfizer
End Stage Renal Disease, Renal Transplant
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response.
- Trial name
- NCT01154387
- Testing
- Anti-Thymocyte Globulin, TOL101, Steroids
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- Tolera Therapeutics, Inc
Kidney Transplantation
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
The 12 Month Core Study (CRAD001A1202) was designed to evaluate the efficacy and safety comparing concentration-controlled everolimus (1.5 mg/day starting dose) with reduced dose cyclosporine and corticosteroids versus 2 g/day…
- Trial name
- NCT00658320
- Testing
- Everolimus, Mycophenolate mofetil (MMF), Basiliximab
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Novartis
Acute Rejection of Renal Transplant
Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient
For patients who meet the inclusion criteria and who agree to participate in this study, the investigators sampled peripheral blood 10cc and performed the analysis for immunologic profile just before the conversion of immune…
- Trial name
- NCT01592253
- Testing
- Sirolimus
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital
End-stage Renal Disease
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation
Chronic renal failure is a major public health problem in industrialized countries, due to its frequency - about 3 million patients in France - and its socio-economic impact.
- Trial name
- ECLAT (NCT03994497)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Angers
Kidney Disease, End-Stage, Donor Specific Antibodies
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection…
- Conditions
- Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant
- Trial name
- NCT04665310
- Testing
- Envarsus XR
- Volunteers
- 46 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Diseases
Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection
The present study investigates the safety and efficacy of steroid withdrawal at six days post-transplant in pediatric renal recipients under concomitant immunosuppression based on antibodies anti IL2 (interleukin 2), Tacrolimus…
- Trial name
- NCT00707759
- Testing
- Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone, Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone
- Where
- Chile
- Volunteers
- 28 people
- Sponsor
- Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
Renal Transplantation, Graft Rejection
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Trial name
- NCT00089947
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Genzyme, a Sanofi Company
Kidney Transplant, Rejection of Renal Transplant
Development and Validation of HistoMX, a Gene-Expression Platform for Molecular Interpretation of Kidney Allograft Biopsies
This retrospective multicentre observational study developed and validated HistoMX, an automated gene-expression-based platform for multidimensional molecular interpretation of kidney allograft biopsies.
- Conditions
- Kidney Transplant, Rejection of Renal Transplant, Antibody Mediated Rejection, BK Virus Nephropathy
- Trial name
- HistoMX (NCT07700563)
- Volunteers
- 2,410 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Chronic Renal Failure
The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes
Several studies have shown that about 30% of transplanted kidneys with stable function present with tubule-interstitial mononuclear cell infiltration in protocol biopsies and therefore meet criteria for acute rejection.
- Trial name
- NCT02664493
- Testing
- Methylprednisolone
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Samsung Medical Center
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Rejection Acute Renal, Rejection Chronic Renal
Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients
This is a multinational, multi-center, observational cohort study. Kidney allograft rejection is poorly detected by standard-of-care biomarkers.
- Conditions
- Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
- Trial name
- VALiDATE (NCT07805343)
- Testing
- Donor-derived cell-free DNA
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
After a kidney or a kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection.
- Trial name
- TACKLE-IT (NCT06474273)
- Testing
- Methylprednisolone, Prednisone
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 540 people
- Sponsor
- University of Sydney